Lung cancer drug lorbrena under safety spotlight in 1,290 patients

NCT ID NCT03844464

Completed Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This completed study looked at side effects of the lung cancer drug Lorbrena in 1,290 patients. Researchers focused on nervous system problems and liver damage. The goal was to understand what factors might increase these risks during real-world use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lorbrena (lorlatinib)
What this could lead to: If successful, this study could help doctors better manage side effects of Lorbrena in lung cancer patients.
What could go wrong: This is an observational study after the drug was already approved, so it does not test new treatments or cures. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

3-22-7, Yoyogi, Shibuya-ku

Tokyo, 151-8589, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.